Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Cuts Q3 Loss

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that it had cut its net loss around 16 percent for the third-quarter, while the firm brought in no revenues for the period.

The Tel Aviv, Israel-based drug discovery informatics and drug development firm posted a net loss of $1.6 million, or $.05 per share, for the three-month period ended Sept. 30, compared to a net loss of $1.9 million, or $.06 per share, for the third quarter of 2009.

Its R&D spending for the quarter was $1.5 million compared to $1.4 million, while its SG&A expenses were $898,000 compared to $757,000.

"Substantial efforts during 2010 have been directed to planning and initiating a program to substantially increase the value of our discoveries by advancing selected molecules beyond the animal disease model proof of concept, something we have not previously done," Anat Cohen-Dayag, Compugen's president and CEO, said in a statement. "Also, with respect to other commercialization activities, we are currently in discussions with various companies regarding both licensing of certain product candidates and 'discovery on demand' collaborations."

Compugen finished the quarter with $21.4 million in cash, cash equivalents, short-term deposits, and marketable securities.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more